Optimizing isoniazid dosing for tuberculosis prevention using genetic testing
Point-of-care pharmacogenomic testing to optimize isoniazid dosing for tuberculosis prevention
['FUNDING_R21'] · STANFORD UNIVERSITY · NIH-10709589
This study is looking to find the best dose of isoniazid, a medicine that helps prevent tuberculosis, by using a quick genetic test to see how your body processes the drug, so that people in Brazil can get a treatment that works best for them with fewer side effects.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10709589 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the dosing of isoniazid, a key medication for tuberculosis prevention, by using pharmacogenomic testing to tailor treatment based on individual genetic profiles. The study aims to validate a rapid diagnostic test that identifies genetic variations affecting drug metabolism in a diverse population in Brazil. By analyzing non-invasive samples, such as fingerstick blood and oral swabs, the research seeks to determine the best isoniazid dose for each patient, reducing the risk of side effects and treatment failures. This personalized approach could lead to better health outcomes for those at risk of tuberculosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of tuberculosis who may benefit from personalized isoniazid dosing based on their genetic makeup.
Not a fit: Patients who do not have a risk of tuberculosis or those who cannot provide the necessary genetic samples may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective tuberculosis prevention strategies tailored to individual genetic profiles.
How similar studies have performed: Previous research has shown promise in using pharmacogenomic approaches to optimize drug dosing, indicating that this method could be effective in improving treatment outcomes.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ANDREWS, JASON RANDOLPH — STANFORD UNIVERSITY
- Study coordinator: ANDREWS, JASON RANDOLPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.